A Clinician's Perspective on the Use of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis

Journal of Clinical Densitometry

Volumn 11, Issue 4, 2008, Pages 478-484

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

Bisphosphonates; osteoporosis; treatment; zoledronate; zoledronic acid

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RECLAST; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOL; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE NECROSIS; CREATININE BLOOD LEVEL; DRUG COST; FEMALE; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; VERTEBRA FRACTURE; WOUND HEALING IMPAIRMENT;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 55549133242     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2008.07.003     Document Type: Article

References (37)

1. WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (1994), World Health Organization, Geneva
2. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 7041 (1996) 1254-1259
3. Baim S., Binkley N., Bilezikian J.P., et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 position development conference. J Clin Densitom 11 1 (2008) 75-91
4. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis (2003), National Osteoporosis Foundation, Washington, DC
5. Kanis J.A., Johnell O., Oden A., et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12 12 (2001) 989-995
6. Black D.M., Arden N.K., Palermo L., et al. Prevalent vertebral deformities predict hip fractures and new vertebral fractures but not wrist fractures. J Bone Miner Res 14 (1999) 821-828
7. Lindsay R., Silverman S.L., Cooper C., et al. Risk of new vertebral fracture in the year following a fracture. JAMA 285 (2001) 320-323
8. Rodan G.A., and Reszka A.A. Bisphosphonate mechanism of action. Curr Mol Med 2 3 (2002) 571-577
9. US Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general (2004), US Department of Health and Human Services, Office of the Surgeon General, Rockville, MD
10. Gehlbach S.H., Avrunin J.S., Puleo E., and Spaeth R. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int 18 6 (2007) 805-810
11. Bahl S., Coates P.S., and Greenspan S.L. The management of osteoporosis following hip fracture: have we improved our care?. Osteoporos Int 14 11 (2003) 884-888
12. Morris C.A., Carrino J.A., Lang P., and Solomon D.H. Incidental vertebral fractures on chest radiographs. Recognition, documentation, and treatment. J Gen Intern Med 21 4 (2006) 352-356
13. Kothawala P., Badamgarav E., Ryu S., et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82 12 (2007) 1493-1501
14. Piette J.D., Heisler M., and Wagner T.H. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health 94 10 (2004) 1782-1787
15. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 49 6 (2002) 897-903
16. Horwitz R.I., Viscoli C.M., Berkman L., et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 336 8714 (1990) 542-545
17. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80 7 (2005) 856-861
18. Cramer J.A., Gold D.T., Silverman S.L., and Lewiecki E.M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18 8 (2007) 1023-1031
19. Downey T.W., Foltz S.H., Boccuzzi S.J., et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99 6 (2006) 570-575
20. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 5 (2005) 487-497
21. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 8 (2006) 1013-1022
22. Lewiecki E.M. Medications don't work if patients don't take them. South Med J 100 12 (2007) 1190-1191
23. Penning-van Beest F.J., Goettsch W.G., Erkens J.A., and Herings R.M. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28 2 (2006) 236-242
24. Cooper A., Drake J., and Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60 8 (2006) 896-905
25. Reginster J.Y., Rabenda V., and Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38 4 Suppl 1 (2006) S2-S6
26. Simon J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24 11 (2002) 1871-1886
27. Delmas P.D., Adami S., Strugala C., et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54 6 (2006) 1838-1846
28. Chesnut III C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 8 (2004) 1241-1249
29. Cauza E., Etemad M., Winkler F., et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther 29 5 (2004) 431-436
30. Miller R.G., Chretien K.C., Meoni L.A., et al. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. J Clin Rheumatol 11 1 (2005) 2-7
31. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 1 (1976) 31-41
32. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 18 (2007) 1809-1822
33. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 10 (2007) 1479-1489
34. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357 18 (2007) 1799-1809
35. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis (2008), National Osteoporosis Foundation, Washington, DC
36. MacLean C., Newberry S., Maglione M., et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148 3 (2008) 197-213
37. Thiebaud D., Sauty A., Burckhardt P., et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61 5 (1997) 386-392